Literature DB >> 17314276

Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.

Antoinette Hollestelle1, Fons Elstrodt, Jord H A Nagel, Wouter W Kallemeijn, Mieke Schutte.   

Abstract

Constitutive activation of the phosphatidylinositol-3-OH kinase (PI3K) and RAS signaling pathways are important events in tumor formation. This is illustrated by the frequent genetic alteration of several key players from these pathways in a wide variety of human cancers. Here, we report a detailed sequence analysis of the PTEN, PIK3CA, KRAS, HRAS, NRAS, and BRAF genes in a collection of 40 human breast cancer cell lines. We identified a surprisingly large proportion of cell lines with mutations in the PI3K or RAS pathways (54% and 25%, respectively), with mutants for each of the six genes. The PIK3CA, KRAS, and BRAF mutation spectra of the breast cancer cell lines were similar to those of colorectal cancers. Unlike in colorectal cancers, however, mutational activation of the PI3K pathway was mutually exclusive with mutational activation of the RAS pathway in all but 1 of 30 mutant breast cancer cell lines (P = 0.001). These results suggest that there is a fine distinction between the signaling activators and downstream effectors of the oncogenic PI3K and RAS pathways in breast epithelium and those in other tissues.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17314276     DOI: 10.1158/1541-7786.MCR-06-0263

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  143 in total

1.  Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy.

Authors:  Danielle B Ulanet; Dale L Ludwig; C Ronald Kahn; Douglas Hanahan
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-10       Impact factor: 11.205

2.  Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer.

Authors:  Todd W Miller; Bryan T Hennessy; Ana M González-Angulo; Emily M Fox; Gordon B Mills; Heidi Chen; Catherine Higham; Carlos García-Echeverría; Yu Shyr; Carlos L Arteaga
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

3.  Update on the molecular profile of the MDA-MB-453 cell line as a model for apocrine breast carcinoma studies.

Authors:  Semir Vranic; Zoran Gatalica; Zhao-Yi Wang
Journal:  Oncol Lett       Date:  2011-11       Impact factor: 2.967

Review 4.  Wnt signaling in mammary glands: plastic cell fates and combinatorial signaling.

Authors:  Caroline M Alexander; Shruti Goel; Saja A Fakhraldeen; Soyoung Kim
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-10-01       Impact factor: 10.005

5.  Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models.

Authors:  Colin Walsh; Isabelle Tanjoni; Sean Uryu; Alok Tomar; Ju-Ock Nam; Hong Luo; Angelica Phillips; Neela Patel; Cheni Kwok; Gerald McMahon; Dwayne G Stupack; David D Schlaepfer
Journal:  Cancer Biol Ther       Date:  2010-05-15       Impact factor: 4.742

6.  The RasGAP gene, RASAL2, is a tumor and metastasis suppressor.

Authors:  Sara Koenig McLaughlin; Sarah Naomi Olsen; Benjamin Dake; Thomas De Raedt; Elgene Lim; Roderick Terry Bronson; Rameen Beroukhim; Kornelia Polyak; Myles Brown; Charlotte Kuperwasser; Karen Cichowski
Journal:  Cancer Cell       Date:  2013-09-09       Impact factor: 31.743

7.  Igf1r as a therapeutic target in a mouse model of basal-like breast cancer.

Authors:  Apostolos Klinakis; Matthias Szabolcs; Guoying Chen; Shouhong Xuan; Hanina Hibshoosh; Argiris Efstratiadis
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-27       Impact factor: 11.205

8.  Lipocalin 2 promotes breast cancer progression.

Authors:  Jiang Yang; Diane R Bielenberg; Scott J Rodig; Robert Doiron; Matthew C Clifton; Andrew L Kung; Roland K Strong; David Zurakowski; Marsha A Moses
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-23       Impact factor: 11.205

9.  Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer.

Authors:  Rong Wu; Suzanne J Baker; Tom C Hu; Kyle M Norman; Eric R Fearon; Kathleen R Cho
Journal:  Am J Pathol       Date:  2013-04       Impact factor: 4.307

10.  Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition.

Authors:  Olga K Mirzoeva; Debopriya Das; Laura M Heiser; Sanchita Bhattacharya; Doris Siwak; Rina Gendelman; Nora Bayani; Nicholas J Wang; Richard M Neve; Yinghui Guan; Zhi Hu; Zachary Knight; Heidi S Feiler; Philippe Gascard; Bahram Parvin; Paul T Spellman; Kevan M Shokat; Andrew J Wyrobek; Mina J Bissell; Frank McCormick; Wen-Lin Kuo; Gordon B Mills; Joe W Gray; W Michael Korn
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.